Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CXCR5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CXCR5 Extracellular Domain (ECD) / Loop Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. |
View CXCR5 Products |
| Gene Delivery | CXCR5 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and native GPCR conformation. |
View CXCR5 Products |
| Benchmark Ab | Anti-CXCR5 (Sequence of PF-06835375 / GSK3858279) Recombinant positive control for binding and functional assays. |
View CXCR5 Products |
| Validator | CXCR5 siRNA Set For knockdown verification in functional assays. |
View CXCR5 Products |
| Related Target A | CXCL13 Cognate chemokine ligand for CXCR5 activation and chemotaxis assays. |
View CXCL13 Products |
| Related Target B | CXCR4 Homologous GPCR for selectivity and off-target counter-screening. |
View CXCR4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Multi-pass Membrane Conformation | High-titer Lentivirus for stable cell line development (Flow Cytometry & Calcium Flux verified). |
| Subfamily Counter-screening | Homolog panel proteins (CXCR4, CXCR3) strictly sequence-verified. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for target knockdown and specificity checks. |
Live CXCR5/CD185 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CXCR5 therapeutics is intensifying, with major players shifting focus from traditional systemic immunosuppression to targeted B-cell and follicular helper T (Tfh) cell modulation. As first-generation therapies reach the clinic, the next wave of R&D is targeting CXCR5 in autoimmune diseases like Systemic Lupus Erythematosus (SLE) and Sjögren's Syndrome, as well as B-cell malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Pfizer, GSK | Lupus Nephritis, Sjögren's Syndrome | Receptor Occupancy & Ligand Blockade (Need Lentivirus for Cell-based Assays) |
| Bispecific Antibody | Inovio, Roche | Lymphoma, Solid Tumors | Dual-Target Binding Validation (Need High-Purity CXCL13 and CXCR5-expressing cells) |
| Small Molecule Antagonists | Academic / Biotech | Inflammatory Diseases | Calcium Flux & Chemotaxis Inhibition (Need Stable GPCR Expression Systems) |